ES2736166T3 - Métodos de producción de disoluciones madre de virus diminuto de ratón (MMV) de alta pureza y alto título y métodos de uso de los mismos - Google Patents
Métodos de producción de disoluciones madre de virus diminuto de ratón (MMV) de alta pureza y alto título y métodos de uso de los mismos Download PDFInfo
- Publication number
- ES2736166T3 ES2736166T3 ES11162488T ES11162488T ES2736166T3 ES 2736166 T3 ES2736166 T3 ES 2736166T3 ES 11162488 T ES11162488 T ES 11162488T ES 11162488 T ES11162488 T ES 11162488T ES 2736166 T3 ES2736166 T3 ES 2736166T3
- Authority
- ES
- Spain
- Prior art keywords
- virus
- tcidaü
- tcid
- less
- mmv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000700605 Viruses Species 0.000 title claims abstract description 465
- 238000000034 method Methods 0.000 title claims abstract description 152
- 239000011550 stock solution Substances 0.000 title claims abstract description 85
- 238000004519 manufacturing process Methods 0.000 title description 39
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 96
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 96
- 230000003612 virological effect Effects 0.000 claims abstract description 43
- 239000012535 impurity Substances 0.000 claims abstract description 35
- 239000000872 buffer Substances 0.000 claims abstract description 31
- 238000005498 polishing Methods 0.000 claims abstract description 23
- 238000005199 ultracentrifugation Methods 0.000 claims abstract description 20
- 238000000108 ultra-filtration Methods 0.000 claims abstract description 17
- 239000012228 culture supernatant Substances 0.000 claims abstract description 15
- 210000002966 serum Anatomy 0.000 claims abstract description 12
- 230000001376 precipitating effect Effects 0.000 claims abstract description 6
- 230000006037 cell lysis Effects 0.000 claims abstract description 5
- 239000012141 concentrate Substances 0.000 claims abstract description 5
- 238000012360 testing method Methods 0.000 claims description 51
- 238000003379 elimination reaction Methods 0.000 claims description 49
- 239000012528 membrane Substances 0.000 claims description 43
- 230000008569 process Effects 0.000 claims description 38
- 239000000243 solution Substances 0.000 claims description 38
- 230000008030 elimination Effects 0.000 claims description 30
- 230000002779 inactivation Effects 0.000 claims description 12
- 239000011159 matrix material Substances 0.000 claims description 8
- 239000012501 chromatography medium Substances 0.000 claims description 6
- 238000005277 cation exchange chromatography Methods 0.000 claims description 4
- 239000011324 bead Substances 0.000 claims description 3
- 239000002244 precipitate Substances 0.000 claims description 3
- 239000000523 sample Substances 0.000 description 86
- 210000004027 cell Anatomy 0.000 description 49
- 238000002360 preparation method Methods 0.000 description 43
- 238000010200 validation analysis Methods 0.000 description 37
- 238000011156 evaluation Methods 0.000 description 35
- 238000007792 addition Methods 0.000 description 27
- 239000002609 medium Substances 0.000 description 21
- 239000000203 mixture Substances 0.000 description 21
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 20
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 20
- 239000012091 fetal bovine serum Substances 0.000 description 19
- 239000006166 lysate Substances 0.000 description 18
- 239000003463 adsorbent Substances 0.000 description 15
- 238000005341 cation exchange Methods 0.000 description 14
- 208000015181 infectious disease Diseases 0.000 description 14
- 239000000463 material Substances 0.000 description 14
- 239000000047 product Substances 0.000 description 14
- 239000007985 Tris NaCl EDTA buffer Substances 0.000 description 11
- 229960000074 biopharmaceutical Drugs 0.000 description 11
- 238000004113 cell culture Methods 0.000 description 11
- 238000000746 purification Methods 0.000 description 11
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 11
- XHZPRMZZQOIPDS-UHFFFAOYSA-N 2-Methyl-2-[(1-oxo-2-propenyl)amino]-1-propanesulfonic acid Chemical compound OS(=O)(=O)CC(C)(C)NC(=O)C=C XHZPRMZZQOIPDS-UHFFFAOYSA-N 0.000 description 10
- 239000004695 Polyether sulfone Substances 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 239000000706 filtrate Substances 0.000 description 10
- 230000014759 maintenance of location Effects 0.000 description 10
- 229920006393 polyether sulfone Polymers 0.000 description 10
- 230000008859 change Effects 0.000 description 9
- 239000000499 gel Substances 0.000 description 9
- 230000002458 infectious effect Effects 0.000 description 9
- 238000001556 precipitation Methods 0.000 description 9
- 239000013049 sediment Substances 0.000 description 9
- 238000010790 dilution Methods 0.000 description 8
- 239000012895 dilution Substances 0.000 description 8
- 238000005119 centrifugation Methods 0.000 description 7
- 239000012530 fluid Substances 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 238000003556 assay Methods 0.000 description 6
- 239000006143 cell culture medium Substances 0.000 description 6
- 238000004587 chromatography analysis Methods 0.000 description 6
- 238000010828 elution Methods 0.000 description 6
- 239000007983 Tris buffer Substances 0.000 description 5
- 239000000356 contaminant Substances 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- ZIUHHBKFKCYYJD-UHFFFAOYSA-N n,n'-methylenebisacrylamide Chemical compound C=CC(=O)NCNC(=O)C=C ZIUHHBKFKCYYJD-UHFFFAOYSA-N 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 5
- 208000002109 Argyria Diseases 0.000 description 4
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 4
- 239000010836 blood and blood product Substances 0.000 description 4
- 229940125691 blood product Drugs 0.000 description 4
- 239000013592 cell lysate Substances 0.000 description 4
- 238000011109 contamination Methods 0.000 description 4
- 238000009295 crossflow filtration Methods 0.000 description 4
- 230000000120 cytopathologic effect Effects 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 239000004332 silver Substances 0.000 description 4
- 229910052709 silver Inorganic materials 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- ZYFVNVRFVHJEIU-UHFFFAOYSA-N PicoGreen Chemical compound CN(C)CCCN(CCCN(C)C)C1=CC(=CC2=[N+](C3=CC=CC=C3S2)C)C2=CC=CC=C2N1C1=CC=CC=C1 ZYFVNVRFVHJEIU-UHFFFAOYSA-N 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000009089 cytolysis Effects 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 230000007717 exclusion Effects 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 238000004062 sedimentation Methods 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000004448 titration Methods 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- 239000013621 viresolve pro solution Substances 0.000 description 3
- 108090000565 Capsid Proteins Proteins 0.000 description 2
- 102100023321 Ceruloplasmin Human genes 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 241000702619 Porcine parvovirus Species 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- 239000012574 advanced DMEM Substances 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000005349 anion exchange Methods 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000005352 clarification Methods 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 238000011018 current good manufacturing practice Methods 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000001728 nano-filtration Methods 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- -1 polyethylene Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000012465 retentate Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 239000003656 tris buffered saline Substances 0.000 description 2
- 238000009736 wetting Methods 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 1
- 238000000035 BCA protein assay Methods 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 238000013382 DNA quantification Methods 0.000 description 1
- 206010053317 Hydrophobia Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 239000007984 Tris EDTA buffer Substances 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000011210 chromatographic step Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000005289 controlled pore glass Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000012527 feed solution Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000011544 gradient gel Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- NBQNWMBBSKPBAY-UHFFFAOYSA-N iodixanol Chemical compound IC=1C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C(I)C=1N(C(=O)C)CC(O)CN(C(C)=O)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NBQNWMBBSKPBAY-UHFFFAOYSA-N 0.000 description 1
- 229960004359 iodixanol Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012092 media component Substances 0.000 description 1
- 238000002941 microtiter virus yield reduction assay Methods 0.000 description 1
- 230000010807 negative regulation of binding Effects 0.000 description 1
- 244000309711 non-enveloped viruses Species 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000009928 pasteurization Methods 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000012805 post-processing Methods 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 239000013017 sartobind Substances 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 239000013026 undiluted sample Substances 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 238000011100 viral filtration Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/02—Recovery or purification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14311—Parvovirus, e.g. minute virus of mice
- C12N2750/14351—Methods of production or purification of viral material
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32422010P | 2010-04-14 | 2010-04-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2736166T3 true ES2736166T3 (es) | 2019-12-26 |
Family
ID=44148425
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES11162488T Active ES2736166T3 (es) | 2010-04-14 | 2011-04-14 | Métodos de producción de disoluciones madre de virus diminuto de ratón (MMV) de alta pureza y alto título y métodos de uso de los mismos |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9644187B2 (enExample) |
| EP (1) | EP2377927B1 (enExample) |
| JP (3) | JP2013523175A (enExample) |
| KR (1) | KR101549296B1 (enExample) |
| CN (1) | CN102985536B (enExample) |
| BR (1) | BR112012026095A2 (enExample) |
| ES (1) | ES2736166T3 (enExample) |
| SG (1) | SG184833A1 (enExample) |
| WO (1) | WO2011130119A2 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112012026095A2 (pt) | 2010-04-14 | 2015-09-15 | Emd Millipore Corp | métodos de produção de estoques de vírus de alta pureza e altos títulos e métodos de uso dos mesmos. |
| DE102010046817A1 (de) * | 2010-09-28 | 2012-03-29 | Sartorius Stedim Biotech Gmbh | Verfahren zur Abtrennung von Viren aus einem Kontaminanten enthaltenden flüssigen Medium |
| ES2649466T3 (es) * | 2012-03-13 | 2018-01-12 | Emd Millipore Corporation | Uso de infecciones asistidas por centrifugación para aumentar el título viral |
| US9809800B2 (en) | 2012-11-22 | 2017-11-07 | Asahi Kasei Medical Co., Ltd. | Method for producing parvovirus having high infectivity titer |
| JP6320429B2 (ja) * | 2013-02-22 | 2018-05-09 | エイジェンシー・フォー・サイエンス，テクノロジー・アンド・リサーチ | 負帯電粒子を用いるウイルス調製物のクロマトグラフィー精製 |
| US9632087B2 (en) | 2013-09-10 | 2017-04-25 | MockV Solutions | Methods for evaluating viral clearance from a biopharmaceutical solution employing mock viral particles |
| WO2017077804A1 (ja) * | 2015-11-06 | 2017-05-11 | 旭化成メディカル株式会社 | 高感染価かつ高純度のパルボウイルスの生産方法 |
| DE102016005049B4 (de) | 2016-04-26 | 2020-06-18 | Sartorius Stedim Biotech Gmbh | Verfahren zur Bestimmung des logarithmischen Reduktionswertes LRV eines Größenausschlussfilters |
| EP3299454A1 (en) * | 2016-09-21 | 2018-03-28 | Deutsches Krebsforschungszentrum | Optimized method for large scale production of parvovirus h-1 in an essentially serum-free medium |
| EP3141611A3 (en) * | 2016-10-21 | 2017-05-10 | Bayer Healthcare LLC | Validation of continuous viral clearance |
| US10961512B2 (en) * | 2017-04-17 | 2021-03-30 | Dao-Yao He | Compositions and kits for purification of viral particles from host cells |
| KR102453351B1 (ko) | 2017-07-05 | 2022-10-07 | 에스케이바이오사이언스(주) | 인플루엔자 백신용 바이러스 씨드 스톡의 제조 방법 |
| EP3446710A1 (en) * | 2017-08-25 | 2019-02-27 | Glenmark Pharmaceuticals S.A. | Methods of inactivating viral contaminants |
| CN108841794B (zh) * | 2018-06-08 | 2021-11-30 | 苏州良辰生物医药科技有限公司 | 一种病毒原液的制备方法 |
| JP7588466B2 (ja) * | 2020-01-22 | 2024-11-22 | 旭化成メディカル株式会社 | パルボウイルスの生産方法 |
| CN115176037A (zh) * | 2020-02-28 | 2022-10-11 | 旭化成医疗株式会社 | 病毒清除性能的评价方法 |
| EP4173696A4 (en) * | 2020-06-24 | 2023-12-20 | Asahi Kasei Medical Co., Ltd. | METHOD FOR EVALUATING A SOLUTION CONTAINING PROTEINS |
| EP4214219A1 (en) * | 2020-09-21 | 2023-07-26 | Bayer HealthCare, LLC | Pathogen clearance system and method |
| US12203914B2 (en) | 2020-11-12 | 2025-01-21 | Sartorius Bioanalytical Instruments, Inc. | Viral clearance evaluation for biological medical product preparation processes |
| JP7612001B2 (ja) | 2021-03-26 | 2025-01-10 | 旭化成メディカル株式会社 | ウイルスクリアランス試験の方法 |
| WO2022252098A1 (zh) * | 2021-05-31 | 2022-12-08 | 中国科学院深圳先进技术研究院 | 噬菌体制剂的制备方法、药物组合物以及应用 |
| JP7665143B2 (ja) * | 2021-06-24 | 2025-04-21 | 株式会社島津製作所 | ウイルス試料の濃縮方法 |
Family Cites Families (101)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3622663A (en) | 1968-06-13 | 1971-11-23 | American Home Prod | Purification of viruses on treated calcium dihydrogen orthophosphate monohydrate adsorbent |
| US3919044A (en) | 1973-03-28 | 1975-11-11 | Armour Pharma | Processes for concentrating and purifying viruses and viral antigens |
| SU579309A1 (ru) | 1973-11-16 | 1977-11-05 | Ленинградский Политехнический Институт Им.М.И.Калинина | Способ получени вакцины |
| FR2475572A1 (fr) | 1980-02-11 | 1981-08-14 | Pasteur Institut | Procede pour l'obtention de fragments de virus a enveloppe lipidique, en particulier d'antigenes utilisables comme vaccins, produits obtenus et applications |
| JPS6147186A (ja) | 1984-08-09 | 1986-03-07 | Chemo Sero Therapeut Res Inst | インフルエンザウイルスの精製方法 |
| JPS6147185A (ja) | 1984-08-09 | 1986-03-07 | Chemo Sero Therapeut Res Inst | 日本脳炎ウイルスの精製方法 |
| JPS6147187A (ja) | 1984-08-10 | 1986-03-07 | Chemo Sero Therapeut Res Inst | 狂犬病ウイルスの精製方法 |
| US6265149B1 (en) | 1986-01-22 | 2001-07-24 | Institut Pasteur | In vitro diagnostic methods and kits for the detection of HIV-2-specific antibodies |
| US5824482A (en) | 1986-06-23 | 1998-10-20 | Institut Pasteur | Purification, cloning, and characterization of a novel human immunodeficiency virus LAVMAL |
| US4814268A (en) | 1986-10-06 | 1989-03-21 | Kreider John W | Methods for propagating fastidious human viruses and for producing purified suspensions thereof |
| US4859597A (en) * | 1987-07-27 | 1989-08-22 | Igene Biotechnology, Inc. | Production of phage and phage-associated lysin |
| NZ225583A (en) | 1987-08-06 | 1991-07-26 | Merck & Co Inc | Process for purifying hepatitis a virions (hav) |
| US5268292A (en) | 1988-06-27 | 1993-12-07 | Robertson Betty H | Reproducible generation of high yields of hepatitis A virus by cell culture |
| GB8914968D0 (en) | 1989-06-29 | 1989-08-23 | Connaught Lab | Production of virus and purification of viral envelope proteins for vaccine use |
| US5719051A (en) | 1989-12-22 | 1998-02-17 | Immuno Aktiengesellschaft | Perfusion system and a method for the large scale production of virus or virus antigen |
| DE4003543A1 (de) | 1990-02-06 | 1991-08-08 | Orpegen Med Molekularbioforsch | Verfahren zur abreicherung von viren in loesungen und zur bestimmung der abreicherungsrate von viren |
| US6709811B1 (en) | 1990-05-24 | 2004-03-23 | The United States Of America As Represented By The Department Of Health And Human Services | Versatile reagent for detecting murine leukemia viruses |
| DE69009066T3 (de) | 1990-06-15 | 2001-07-19 | Innogenetics N.V., Gent | SIV cpz-ant Retrovirus und seine Anwendungen. |
| IT1248075B (it) | 1991-06-18 | 1995-01-05 | Sclavo Spa | Processo per la purificazione del virus dell'epatite a (hav), virus cosi` purificato e composizioni vaccinali che lo contengono. |
| FR2686097B1 (fr) | 1992-01-14 | 1994-12-30 | Rhone Merieux | Preparation d'antigenes et de vaccins de virus de la mystery disease, antigenes et vaccins obtenus pour la prevention de cette maladie. |
| US5658779A (en) | 1992-03-20 | 1997-08-19 | Ligochem, Inc. | Method of adsorbing viruses from fluid compositions |
| US5602023A (en) | 1992-03-24 | 1997-02-11 | Csatary; Laszlo K. | Pharmaceutical product containing live, stabilized virus for the therapy of viral and malignant diseases and process for preparing the same |
| ATE174382T1 (de) | 1992-10-06 | 1998-12-15 | Dade Behring Marburg Gmbh | Retrovirus aus der hiv-gruppe und dessen verwendung |
| PT751988E (pt) | 1994-03-22 | 2000-05-31 | Immune Response Corp Inc | Producao e isolamento altamente eficientes de particulas virais |
| FR2723740B1 (fr) | 1994-08-16 | 1996-11-08 | Pasteur Merieux Serums Vacc | Procede de preparation d'antigenes du virus grippal, antigenes obtenus et leurs applications |
| AU704391B2 (en) | 1994-10-28 | 1999-04-22 | Trustees Of The University Of Pennsylvania, The | Improved adenovirus and methods of use thereof |
| US5756341A (en) | 1994-11-10 | 1998-05-26 | Immuno Ag | Method for controlling the infectivity of viruses |
| US5837520A (en) | 1995-03-07 | 1998-11-17 | Canji, Inc. | Method of purification of viral vectors |
| US6281010B1 (en) | 1995-06-05 | 2001-08-28 | The Trustees Of The University Of Pennsylvania | Adenovirus gene therapy vehicle and cell line |
| FR2737730B1 (fr) | 1995-08-10 | 1997-09-05 | Pasteur Merieux Serums Vacc | Procede de purification de virus par chromatographie |
| US5840565A (en) | 1995-08-22 | 1998-11-24 | The Regents Of The University Of California | Methods for enhancing the production of viral vaccines in PKR-deficient cell culture |
| WO1997008298A1 (en) | 1995-08-30 | 1997-03-06 | Genzyme Corporation | Chromatographic purification of adenovirus and aav |
| US6194192B1 (en) | 1996-02-29 | 2001-02-27 | Takara Shuzo Co., Ltd. | Method of purifying and removing viruses |
| EP0904393A4 (en) | 1996-03-29 | 1999-09-08 | Univ Otago | PARAPOXVIRUS VECTORS |
| CZ438398A3 (cs) | 1996-07-01 | 1999-03-17 | Rhone-Poulenc Rorer S. A. | Způsob přípravy rekombinantních adenovirů |
| US7732129B1 (en) | 1998-12-01 | 2010-06-08 | Crucell Holland B.V. | Method for the production and purification of adenoviral vectors |
| DE69737107T2 (de) | 1996-11-20 | 2007-07-12 | Introgen Therapeutics Inc., Austin | Ein verbessertes verfahren zur produktion und reinigung von adenoviralen vektoren |
| FR2756297B1 (fr) | 1996-11-22 | 1999-01-08 | Centre Nat Rech Scient | Procede de production de virus recombinants |
| US6261823B1 (en) | 1996-12-13 | 2001-07-17 | Schering Corporation | Methods for purifying viruses |
| US6544769B1 (en) | 1996-12-13 | 2003-04-08 | Schering Corporation | Compostions comprising viruses and methods for concentrating virus preparations |
| ZA982950B (en) | 1997-04-08 | 1998-10-19 | Merck & Co Inc | Stabilized human papillomavirus formulations |
| US6995006B2 (en) | 1997-09-05 | 2006-02-07 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
| US6410300B1 (en) | 1998-01-12 | 2002-06-25 | The University Of North Carolina At Chapel Hill | Methods and formulations for mediating adeno-associated virus (AAV) attachment and infection and methods for purifying AAV |
| US6037456A (en) | 1998-03-10 | 2000-03-14 | Biosource Technologies, Inc. | Process for isolating and purifying viruses, soluble proteins and peptides from plant sources |
| US5994134A (en) | 1998-05-04 | 1999-11-30 | Canji, Inc. | Viral production process |
| EP1080218A1 (en) | 1998-05-27 | 2001-03-07 | University of Florida | Method of preparing recombinant adeno-associated virus compositions by using an iodixanol gradient |
| PT1105466E (pt) | 1998-08-14 | 2006-07-31 | Merck & Co Inc | Processo para a purificacao de particulas tipo virus do papilomavirus humano |
| US6383794B1 (en) | 1998-08-24 | 2002-05-07 | Uab Research Foundation | Methods of producing high titer recombinant adeno-associated virus |
| WO2000028004A1 (en) | 1998-11-10 | 2000-05-18 | The University Of North Carolina At Chapel Hill | Virus vectors and methods of making and administering the same |
| CN1087032C (zh) * | 1998-12-14 | 2002-07-03 | 彭朝晖 | 一种生产重组腺病毒的方法 |
| FR2787465A1 (fr) | 1998-12-21 | 2000-06-23 | Transgene Sa | Procede d'inactivation des virus enveloppes dans une preparation virale de virus non enveloppes |
| CA2356373A1 (fr) * | 1998-12-31 | 2000-07-13 | Aventis Pharma S.A. | Methode de separation de particules virales |
| US6387368B1 (en) | 1999-02-08 | 2002-05-14 | The Trustees Of The University Of Pennsylvania | Hybrid adenovirus-AAV virus and methods of use thereof |
| US6793926B1 (en) | 1999-05-27 | 2004-09-21 | Genovo, Inc. | Methods for production of a recombinant adeno-associated virus |
| US6316185B1 (en) | 1999-09-29 | 2001-11-13 | Mountain View Pharmaceuticals, Inc. | Quantitation of viruses by light scattering |
| US6861001B2 (en) | 1999-12-02 | 2005-03-01 | The General Hospital Corporation | Methods for removal, purification, and concentration of viruses, and methods of therapy based thereupon |
| CA2395820A1 (en) | 1999-12-29 | 2001-07-05 | Genzyme Corporation | Method using filtration aids for the separation of virus vectors from nucleic acids and other cellular contaminants |
| TWI289158B (en) | 2000-08-10 | 2007-11-01 | Oncolytics Biotech Inc | Method of producing infectious reovirus |
| WO2002018550A1 (en) | 2000-08-25 | 2002-03-07 | The General Hospital Corporation | Selective precipitation of viruses |
| DE10144903A1 (de) | 2001-09-12 | 2003-03-27 | Chiron Behring Gmbh & Co | Vermehrung von Viren in Zellkultur |
| US7195905B2 (en) | 2001-12-10 | 2007-03-27 | Baxter Healthcare S.A. | Enveloped virus vaccine and method for production |
| US6825027B2 (en) | 2001-12-10 | 2004-11-30 | Baxter Healthcare S.A. | Method of production of purified hepatitis a virus particles and vaccine preparation |
| US6951752B2 (en) | 2001-12-10 | 2005-10-04 | Bexter Healthcare S.A. | Method for large scale production of virus antigen |
| WO2003049763A1 (en) | 2001-12-12 | 2003-06-19 | Fh Faulding & Co Limited | Composition for the preservation of viruses |
| WO2003084479A2 (en) | 2002-03-29 | 2003-10-16 | Merck & Co., Inc. | Large scale methods of producing adenovirus and adenovirus seed stocks |
| DE60319210T2 (de) | 2002-03-29 | 2009-02-12 | Merck & Co., Inc. | Verfahren zur virusproduktion |
| ES2323454T5 (es) | 2002-04-30 | 2012-11-14 | Oncolytics Biotech Inc. | Procedimiento mejorado de purificación de virus |
| ATE360683T1 (de) | 2002-05-14 | 2007-05-15 | Merck & Co Inc | Verfahren zur reinigung von adenovirus |
| US7419817B2 (en) | 2002-05-17 | 2008-09-02 | The United States Of America As Represented By The Secretary Department Of Health And Human Services, Nih. | Scalable purification of AAV2, AAV4 or AAV5 using ion-exchange chromatography |
| WO2003103605A2 (en) | 2002-06-07 | 2003-12-18 | Large Scale Biology Corporation | Flexible vaccine assembly and vaccine delivery platform |
| AU2003279240A1 (en) | 2002-06-21 | 2004-01-06 | Genetix Pharmaceuticals, Inc. | Methods for purifying viral particles for gene therapy |
| US20060228334A1 (en) * | 2002-07-10 | 2006-10-12 | Manuel Rosa-Calatrava | Modified adenoviral fiber with ablated to cellular receptors |
| PL215169B1 (pl) | 2002-09-05 | 2013-10-31 | Bavarian Nordic As | Sposób amplifikacji wirusów, kompozycja zawierajaca pokswirusa uzyskanego tym sposobem oraz jego zastosowanie do otrzymywania szczepionki |
| US20050009168A1 (en) | 2003-05-12 | 2005-01-13 | Robbins Joan Marie | Methods and apparatus for Adeno associated virus purification |
| AU2004249199B2 (en) | 2003-06-18 | 2008-07-24 | Onyx Pharmaceuticals, Inc. | Method for purifying virus |
| US20070275449A1 (en) | 2003-10-15 | 2007-11-29 | Vector Gene Technology Company Ltd. | Method for Large-Scale Production, Isolation, Purification and the Uses of Multi-Type Recombinant Adeno-Associated Virus Vectors |
| JP2007515172A (ja) * | 2003-12-23 | 2007-06-14 | シェーリング コーポレイション | 無血清培地懸濁培養において安定なａ５４９細胞株を生成するための方法 |
| WO2005080556A2 (en) | 2004-02-23 | 2005-09-01 | Crucell Holland B.V. | Virus purification methods |
| US20080254067A1 (en) | 2004-05-20 | 2008-10-16 | Id Biomedical Corporation | Process for the Production of an Influenza Vaccine |
| ES2647477T3 (es) | 2004-06-01 | 2017-12-21 | Genzyme Corporation | Composiciones y métodos para prevenir la agregación del vector AAV |
| DE102004049290A1 (de) | 2004-10-09 | 2006-04-20 | Bayer Healthcare Ag | Verfahren zur Herstellung von Virusmaterial |
| US7901921B2 (en) | 2004-10-22 | 2011-03-08 | Oncolytics Biotech Inc. | Viral purification methods |
| WO2006052302A2 (en) | 2004-11-03 | 2006-05-18 | Introgen Therapeutics Inc. | Method of producing and purifying adenoviral vectors |
| US20060281075A1 (en) | 2004-12-22 | 2006-12-14 | Large Scale Biology Corporation | Purification of viruses, proteins and nucleic acids |
| US7344839B2 (en) | 2004-12-23 | 2008-03-18 | Aurx, Inc. | Virus preparations and methods |
| DE602006003420D1 (de) | 2005-04-11 | 2008-12-11 | Crucell Holland Bv | Virusreinigung mit ultrafiltration |
| DE102005047301B4 (de) | 2005-09-30 | 2009-04-16 | Sartorius Stedim Biotech Gmbh | Verfahren zum Nachweis der Virenabreicherung für die Validierung von Filtern und Filtrationsprozessen |
| WO2007059473A2 (en) | 2005-11-12 | 2007-05-24 | Introgen Therapeutics, Inc. | Methods for the production and purification of adenoviral vectors |
| US7754421B2 (en) | 2005-11-18 | 2010-07-13 | National Research Council Of Canada | Detection of intact recombinant viruses |
| KR101157176B1 (ko) | 2005-12-20 | 2012-06-20 | 삼성전자주식회사 | 세포 또는 바이러스의 농축 또는 정제용 미세유동장치 및방법 |
| EP2018421B1 (en) * | 2006-04-28 | 2012-12-19 | The Trustees of the University of Pennsylvania | Scalable production method for aav |
| US7851196B2 (en) | 2006-05-01 | 2010-12-14 | The Regents Of The University Of California | Methods for purifying adeno-associated virus particles |
| CN101516395B (zh) * | 2006-09-01 | 2014-03-26 | 伯哈拉特生物技术国际有限公司 | 抗屈曲病毒感染的疫苗 |
| JP2010512748A (ja) | 2006-12-15 | 2010-04-30 | シェーリング−プラウ・リミテッド | インフルエンザウイルスを培養物中で複製するための方法 |
| WO2008109721A1 (en) * | 2007-03-06 | 2008-09-12 | Introgen Therapeutics, Inc. | Chromatographic methods for assessing adenovirus purity |
| KR20170001720A (ko) * | 2007-03-14 | 2017-01-04 | 다케다 백신즈 인코포레이티드 | 바이러스 유사 입자 정제 |
| EP2134757A2 (en) | 2007-03-27 | 2009-12-23 | University of Maryland, College Park | Imprinted polymeric materials for binding various targets such as viruses |
| EP2155864B1 (en) | 2007-05-04 | 2013-07-17 | Baxter International Inc. | Formulation of sugar solutions for continuous ultracentrifugation for virus purification |
| JP2011511640A (ja) * | 2008-02-12 | 2011-04-14 | サノフィ パストゥール リミテッド | ポックス・ウイルスの精製方法 |
| BR112012026095A2 (pt) | 2010-04-14 | 2015-09-15 | Emd Millipore Corp | métodos de produção de estoques de vírus de alta pureza e altos títulos e métodos de uso dos mesmos. |
| US9651469B1 (en) * | 2016-01-27 | 2017-05-16 | General Electric Company | Electrostatic particle sensor |
-
2011
- 2011-04-08 BR BR112012026095A patent/BR112012026095A2/pt not_active IP Right Cessation
- 2011-04-08 SG SG2012075875A patent/SG184833A1/en unknown
- 2011-04-08 KR KR1020127029690A patent/KR101549296B1/ko not_active Expired - Fee Related
- 2011-04-08 CN CN201180018931.9A patent/CN102985536B/zh not_active Expired - Fee Related
- 2011-04-08 WO PCT/US2011/031747 patent/WO2011130119A2/en not_active Ceased
- 2011-04-08 JP JP2013504963A patent/JP2013523175A/ja active Pending
- 2011-04-08 US US13/082,828 patent/US9644187B2/en not_active Expired - Fee Related
- 2011-04-14 EP EP11162488.8A patent/EP2377927B1/en not_active Revoked
- 2011-04-14 ES ES11162488T patent/ES2736166T3/es active Active
-
2015
- 2015-04-10 JP JP2015081173A patent/JP6284500B2/ja not_active Expired - Fee Related
-
2017
- 2017-07-07 JP JP2017134066A patent/JP6522054B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP6284500B2 (ja) | 2018-02-28 |
| WO2011130119A2 (en) | 2011-10-20 |
| US20120088228A1 (en) | 2012-04-12 |
| CN102985536B (zh) | 2017-12-05 |
| WO2011130119A3 (en) | 2012-03-29 |
| BR112012026095A2 (pt) | 2015-09-15 |
| US9644187B2 (en) | 2017-05-09 |
| JP2017195897A (ja) | 2017-11-02 |
| JP2015126757A (ja) | 2015-07-09 |
| EP2377927A1 (en) | 2011-10-19 |
| JP6522054B2 (ja) | 2019-05-29 |
| CN102985536A (zh) | 2013-03-20 |
| SG184833A1 (en) | 2012-11-29 |
| EP2377927B1 (en) | 2019-05-22 |
| KR20130020954A (ko) | 2013-03-04 |
| WO2011130119A8 (en) | 2011-12-29 |
| JP2013523175A (ja) | 2013-06-17 |
| KR101549296B1 (ko) | 2015-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2736166T3 (es) | Métodos de producción de disoluciones madre de virus diminuto de ratón (MMV) de alta pureza y alto título y métodos de uso de los mismos | |
| ES2588990T3 (es) | Métodos mejorados para la purificación de vectores de AAV recombinantes | |
| Tseng et al. | A fast and efficient purification platform for cell-based influenza viruses by flow-through chromatography | |
| ES2653197T3 (es) | Procedimiento para producir antígeno ortomixoviral y vacunas | |
| CN106574252B (zh) | 从细胞培养物中纯化脊髓灰质炎病毒的方法 | |
| WO2018103619A1 (zh) | 一种口蹄疫疫苗的制备方法 | |
| CN108085301B (zh) | 从宿主细胞提取和纯化腺相关病毒和腺病毒的方法及其组分和试剂盒 | |
| Kalbfuss-Zimmermann et al. | Viral vaccines purification | |
| JP6945626B2 (ja) | 空の粒子の等電点による排除に基づく腫瘍崩壊性ラットパルボウイルスｈ−１の製造および精製のための大規模に実現可能な方法 | |
| WO2021172573A1 (ja) | ウイルスクリアランス性能の評価方法 | |
| Luong et al. | Rapid bench to bedside therapeutic bacteriophage production | |
| JP7588466B2 (ja) | パルボウイルスの生産方法 | |
| CN103052399B (zh) | 用于减少病毒组合物中dna杂质的方法 | |
| RU2614127C2 (ru) | Способ получения концентрата рекомбинантных псевдоаденовирусных частиц, экспрессирующих ген гемагглютинина вируса гриппа A/California/07/2009(H1N1) | |
| Alves | Production, concentration and purification strategies for Bluetongue virus | |
| CN116855461A (zh) | 一种呼肠孤病毒3型的纯化方法及应用 | |
| Shoaebargh et al. | Developing and Optimizing Monolithic Column Chromatography Purification Process for Oncolytic Rhabdoviral Vectors | |
| Salm | Ligands from combinatorial peptide libraries for virus removal | |
| Antunesa | Downstream processing of cell culture-derived animal viruses |